Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-4827 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Part A, MK-4827 + temozolomide dose escalation cohort | EXPERIMENTAL | - |
| Part B, MK-4827 + temozolomide melanoma cohort | EXPERIMENTAL | - |
| Part B, MK-4827 + temozolomide glioblastoma multiforme cohort | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MK-4827 | DRUG | MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme. |
| Temozolomide | DRUG | MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme. |
Inclusion criteria Part A * Participants with histologically-confirmed advanced solid tumors who have failed to respond to standard therapy, or progressed on standard therapy, or for whom standard therapy does not exist. Part B * Participants must have a histologically-confirmed recurrent gliobl...
MK-4827 is an investigational small molecule being studied for the treatment of recurrence of solid tumors, including glioblastoma multiforme and melanoma. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
MK-4827 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 1 clinical trials.
MK-4827 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. One Phase 1 trial has been completed, and the drug is not yet available for commercial use.
MK-4827 has been studied in one clinical trial, identified as NCT01294735. This Phase 1 study, titled "Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)," has been completed and enrolled 19 participants.
MK-4827 is not known to have alternative names. It is a distinct investigational compound developed by Merck & Company, Inc. for oncology indications, and no other names for this drug have been reported.